Nexalin Technology Signs Exclusive Distribution Agreement With Carmi Masha Technologies To Advertise, Sell Nexalin's Gen-2 Console In Israel

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel.

This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a variety of mental health disorders, such as insomnia, depression, and anxiety. Nexalin and Carmi Masha also plan to explore potential future applications of the technology in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), Alzheimer's disease, and other forms of dementia as part of the Company's ongoing global clinical initiatives. Under the terms of the agreement, Carmi Masha will lead all sales, marketing, and clinical education efforts in Israel, as well as manage the importation, registration, and distribution of Nexalin's SYNC device across hospitals, clinics, and private treatment centers.